P900009/S050: SONIC ACCELERATED FRACTURE HEALING SYSTEM MODEL 2A
FDA’s recorded scope: a change in the manufacturing facility associated with the transducer cable assembly for the EXOGEN Ultrasound Bone Healing System.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 3 FDA records to the applicant name Bioventus, LLC. The collection includes 1 510(k) clearance. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 23, 2025 to Aug 26, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code GZF appears in 1 of the 3 linked filings. The collection spans 3 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P170007, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 4721 Emperor Blvd., Suite 100, Durham, NC, 27703, US. Recorded on K253877, decision dated Aug 26, 2026.
Stimulator, Peripheral Nerve, Implanted (Pain Relief); Stimulator, Bone Growth, Non-Invasive; Acid, Hyaluronic, Intraarticular.
FDA’s recorded scope: a change in the manufacturing facility associated with the transducer cable assembly for the EXOGEN Ultrasound Bone Healing System.
FDA’s recorded scope: Approval for the installation of a newer model of distribution pump and new piping connecting the pump, the Water for Injection (WFI) tank, and the heat exchanger utilized in DUROLANE manufacturing.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bioventus, LLC | 510(k) clearance | Aug 26, 2026 | FDA | |
| Bioventus, LLC | PMA supplement | Mar 6, 2026 | FDA | |
DUROLANEP170007/S015 | Bioventus, LLC | PMA supplement | Dec 23, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.